65,437 trials
Meningococcal Meningitis · Measles · Mumps
Primary: Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only) — 98; 98; 95; 95 Percentage of Participants
Meningococcal Meningitis · Measles · Mumps
Primary: Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC) — 96; 93…
Cough · GERD
Primary: Change in Cough-Specific Quality of Life Questionnaire — 9.8; 5.8 participants
Asthma
Primary: Mean Number of Post-index Asthma-related Events Measured Using Medical and Pharmacy Claims — 0.033; 0.046; 0.022; 0.027 Asthma-related events — p=0.0051
Neoplasms, Breast
Primary: Overall Survival (OS) at 53 Months — 27.8; 20.5 months — p=0.0062
Asthma
Primary: Mean Ratio of Controller Medication to Total Asthma Medication — 0.57; 0.66; 0.66; 0.71 ratio
Molluscum Contagiosum, Skin Disease
Primary: Patients Experiencing Complete Clearance of All Molluscum Lesions. — 1; 3 Participants
Cancer · Melanoma
Primary: Progression Free Survival (PFS) — 148; 82 days — p=0.068
Squamous Cell Carcinoma
Primary: Number of Control and Intervention Participants on Skin Self-examination Performance at Follow-up 1 Month After Intervention — 34; 8 Participants
Erectile Dysfunction · Metabolic Syndrome
Primary: Change From Baseline in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Subscore at Week 8 or Last Observation Carried Forward (LOCF)…
Anaplastic Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Number of Patients With Response — 0; 2 participants
Pneumococcal Infections
Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0) — 81; 55; 55; 49 geometric mean titer
Post-Menopausal Osteoporosis
Primary: Relative Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at 12, 24 and 36 Months — 0.7969; 0.7861; 0.8378; 0.8845 Percent change
Healthy
Primary: Cmax of Norethindrone — 4.3306; 4.2282 ng/mL
Myopia
Primary: On-eye Wettability — 1.33; 2.11; 1.70; 2.07 units on a scale